Cargando…
Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United States
INTRODUCTION/BACKGROUND: This study aimed to describe patient and caregiver preferences for treatments of relapsed or refractory multiple myeloma (MM). MATERIALS AND METHODS: A survey including discrete-choice experiment (DCE) and best-worst scaling (BWS) exercises was conducted among US patients wi...
Autores principales: | Auclair, Daniel, Mansfield, Carol, Fiala, Mark A, Chari, Ajai, Cole, Craig E, Kaufman, Jonathan L, Orloff, Gregory J, Siegel, David S, Zonder, Jeffrey A, Mange, Brennan, Yesil, Jennifer, Dalal, Mehul, Mikhael, Joseph R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898176/ https://www.ncbi.nlm.nih.gov/pubmed/35256844 http://dx.doi.org/10.2147/PPA.S345906 |
Ejemplares similares
-
Selinexor in relapsed/refractory multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2020) -
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma
por: Jakubowiak, Andrzej J., et al.
Publicado: (2019) -
Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma
por: Pan, Darren, et al.
Publicado: (2021) -
Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
por: Bhutani, Divaya, et al.
Publicado: (2017) -
Patient‐Reported Factors in Treatment Satisfaction in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
por: Chari, Ajai, et al.
Publicado: (2019)